Protein Kinase Inhibitors Development Services

Compared to traditional chemotherapy, targeted drugs provide efficacy and safety advantages, making them a leukemia drug research hotspot. Since the approval of the first tyrosine kinase inhibitor in 2001, there has been a growing interest in developing small molecular targeted drugs for leukemia therapy. Ongoing clinical trials of protein kinase inhibitors offer promising prospects as novel leukemia therapeutics.

Fig. 1. Activation of different protein kinase-dependent pathways. (Zhong, L. et al., 2021)

Our Services

Alfa Cytology provides a comprehensive solution for leukemia research, specializing in protein kinase inhibitor development. Our services cover all stages of drug discovery and development, including computer-aided design, virtual screening, target screening, drug structure analysis, pharmacological experiments, and compound optimization. Explore our range of services based on your research needs.

FLT3 Inhibitors Development

We offer development services for FLT3 inhibitors, discover possible drug candidates, and verify their ability to inhibit FLT3.

IDH Inhibitions Development

Depending on your specific requirements, we can assist in developing inhibitors targeting IDH1 or IDH2 mutants, which are known to increase 2-HG levels and impact tumor redifferentiation.

BCL-2 Inhibitors Development

We provide BCL2 inhibitor development services to expedite the process of drug development, enabling faster progress in developing effective leukemia therapy.

BCR-ABL Inhibitors Development

In order to find effective therapeutics for leukemia, especially chronic myelogenous leukemia (CML), we offer development of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogene.

BTK Inhibitors Development

The discovery service of BTK inhibitors can help you identify and optimize potential therapeutics for B-cell malignant tumors and autoimmune diseases.

PI3K Inhibitors Development

Our target recognition and verification services play a crucial role in accelerating the discovery of PI3K inhibitors specifically tailored for leukemia therapy.

Structure and Functional Analysis

We provide additional analytical services for protein structure and function, which helps to provide supporting information for the mechanism of action of protein kinase inhibitors.

Evaluation of Inhibitors for Leukemia

Our expert team employs a comprehensive approach to assess the efficacy, safety, and mechanism of action of potential inhibitors.

Advantages of Our Services

We possess various types of compound libraries, including diverse collections of compounds.
We have access to high-performance computer servers and extensive database resources.
Our team comprises skilled professionals in molecular simulation and drug design.
Our well-equipped laboratories and advanced technologies enable efficient drug discovery and development
Our comprehensive service offering covers the entire drug development continuum, saving time and resources.

Alfa Cytology's protein kinase inhibitors development service offers a comprehensive and tailored approach to assist pharmaceutical companies, academic institutions, and research organizations in their quest to develop effective small molecule targeted therapies for various types of leukemia. Please contact us if you have any special requirements regarding our services.

Reference

Zhong, L.; et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Sig Transduct Target Ther. 2021, 6: 201.

For research use only. Not intended for any clinical use.